In recent years, numerous studies have emerged on the management of type 2 diabetes mellitus (T2DM) and obesity.According to Professor Andreas Liebl, the most noteworthy advances currently come from the development of a new generation of incretin-based drugs, including GLP‑1 receptor agonists, GIP receptor agonists, and in the future, possibly even triple agonists that also act on the glucagon receptor.
This class of drugs is landmark: they not only effectively lower blood glucose and induce significant weight loss, but have also been proven to exert clear cardiovascular and renal protective effects.
Accordingly, a major shift in treatment philosophy has occurred:from focusing solely on blood glucose and body weight to emphasizing holistic cardio‑renal‑metabolic protection.
This benefit is seen not only with GLP‑1/GIP dual receptor agonists but also with SGLT‑2 inhibitors, making them important current therapeutic options.Today, our clinical perspective on patients is more comprehensive.We no longer focus only on blood glucose or weight, but integrate multiple dimensions to manage patients in a more holistic manner.
Finally, we now have practical tools to translate research findings into clinical practice.The application of various digital tools and structured treatment protocols has effectively promoted the translation of research conclusions into routine clinical care, and the impact of this translation is becoming increasingly prominent.